Pieris Pharmaceuticals, Inc , a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs.
infoPieris Pharmaceuticals is a micro cap stock with a total market cap of 43.40M.
infoThey trade on the NASDAQ and had their IPO 8 years and 7 months ago.
infoPieris Pharmaceuticals currently employs 127 people.
infoAs of Wednesday, Aug 23 2023, Pieris Pharmaceuticals’s share price is $0.439.
News Relating to Pieris Pharmaceuticals
Zacks Investment Research
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here’s What You Should Know
Wednesday Aug 23 2023 at 13:32
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks Investment Research
New Strong Buy Stocks for August 23rd
Wednesday Aug 23 2023 at 08:16
JHX, CWCO, GPI, CEG and PIRS have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2023.
PennyStocks
Penny Stocks To Buy This Week? 4 To Watch Under $5
Tuesday Aug 22 2023 at 10:51
If you’re looking for penny stocks to buy this week, you’ve got your work cut out for yourself. Plenty of headwinds will be faced, including more tech earnings and Friday’s speech from Fed Chair Jerome Powell.
Zacks Investment Research
New Strong Buy Stocks for August 16th
Wednesday Aug 16 2023 at 07:58
GM, IBN, PIRS, GPI and MBWM have been added to the Zacks Rank #1 (Strong Buy) List on August 16, 2023.
Zacks Investment Research
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
Wednesday Jul 19 2023 at 09:52
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
Zacks Investment Research
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
Friday Jun 23 2023 at 11:54
Pieris’ (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.
Accesswire
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Friday Jun 02 2023 at 16:30
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory and cancer diseases, today announced that Stephen Yoder, president and chief executive officer of Pieris, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York City.
Seeking Alpha
Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites
Wednesday May 17 2023 at 00:55
Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company’s cash burn rate.
PennyStocks
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
Friday May 12 2023 at 11:16
Penny stocks under $1 to watch before next week. The post Best Penny Stocks To Buy Now?
PennyStocks
Best Penny Stocks to Buy? 3 Under $1 To Watch Before Next Week
Thursday May 11 2023 at 13:23
Penny stocks under $1 to watch right now. The post Best Penny Stocks to Buy?
Zacks Investment Research
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Wednesday May 10 2023 at 09:56
Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago.
Accesswire
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Tuesday May 02 2023 at 16:30
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its first quarter 2023 investor call on Wednesday, May 10, 2023, at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial 866-682-6100 (Toll Free US & Canada) or +1 862-298-0702 (International) at least five minutes prior to the start of the call.
Seeking Alpha
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
Wednesday Mar 29 2023 at 15:40
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures – Senior Vice President and Chief Financial Officer Stephen Yoder – President and Chief Executive Officer Mary Fitzgerald – Vice President, Project Leader Elarekibep Conference Call Participants Roger Song – Jefferies Jonathan Miller – Evercore ISI Rob Andrew – William Blair & Company Operator Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Conference Call and Webcast. [Operator Instructions].
Zacks Investment Research
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
Wednesday Mar 29 2023 at 09:59
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Accesswire
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Wednesday Nov 23 2022 at 08:00
BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 12:10 PM ET. A webcast of the company’s presentation will be available at this link.
Seeking Alpha
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Call Transcript
Wednesday Nov 02 2022 at 12:23
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Thomas Bures – SVP & CFO Stephen Yoder – CEO, President & Director Shane Olwill – SVP & Chief Development Officer Conference Call Participants Jonathan Miller – Evercore ISI Matthew Phipps – William Blair & Company Jiale Song – Jefferies Operator Good day, ladies and gentlemen, and welcome to the Pieris Pharmaceuticals, Inc. Third Quarter Earnings Call. [Operator Instructions].
Accesswire
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Wednesday Oct 26 2022 at 08:00
BOSTON, MA / ACCESSWIRE / October 26, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial (888) 645-4404 (Toll Free US & Canada) or (862) 298-0702 (International) at least five minutes prior to the start of the call.
Accesswire
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Thursday Sep 08 2022 at 16:01
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 12:30 PM EDT.
Seeking Alpha
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results – Earnings Call Transcript
Saturday Aug 06 2022 at 17:14
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Tom Bures – Chief Financial Officer Steve Yoder – President and Chief Executive Officer Hitto Kaufmann – Chief Scientific Officer Shane Olwill – Chief Development Officer Conference Call Participants Roger Song – Jefferies Jonathan Miller – Evercore ISI Matt Phipps – William Blair Operator Good morning, ladies and gentlemen, and welcome to the Pieris Pharmaceuticals Second Quarter Earnings Call. I will now turn the program over to Tom Bures, Chief Financial Officer.
Zacks Investment Research
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
Thursday Aug 04 2022 at 11:18
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Accesswire
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
Thursday Jul 28 2022 at 07:20
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial (800) 285-6670 (Toll Free US & Canada) or (713) 481-1320 (International) at least five minutes prior to the start of the call.
Accesswire
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
Thursday Jun 02 2022 at 08:00
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM EDT. A webcast of the company’s presentation will be available at this link.
Zacks Investment Research
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
Wednesday May 18 2022 at 11:17
Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Accesswire
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
Wednesday May 18 2022 at 08:00
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 9:30 AM EDT.
Zacks Investment Research
After Plunging 45.5% in 4 Weeks, Here’s Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)
Monday May 16 2022 at 11:17
The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Seeking Alpha
Pieris Pharmaceuticals, Inc (PIRS) CEO Stephen S. Yoder on Q1 2022 Results – Earnings Call Transcript
Wednesday May 11 2022 at 10:43
Pieris Pharmaceuticals, Inc (NASDAQ:PIRS ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Stephen S. Yoder – Chief Executive Officer, President, Director Thomas Bures – Senior Vice President, Chief Financial Officer Tim Demuth – Chief Medical Officer Conference Call Participants Jessica Hanitta Hui – Evercore ISI Roger Jiale Song – Jefferies Matthew Phipps – William Blair & Company Operator Good day and welcome to your Pieris Pharmaceuticals, Inc. First Quarter Earnings Call.
Zacks Investment Research
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Wednesday May 11 2022 at 09:47
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Accesswire
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
Wednesday May 04 2022 at 08:00
BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2022 investor call on Wednesday, May 11, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial (888) 428-7458 (Toll Free US & Canada) or (862) 298-0702 (International) at least five minutes prior to the start of the call.
The Motley Fool
This Pharmaceutical Stock Could Be Your Lottery Ticket
Saturday Apr 09 2022 at 06:00
Pieris Pharmaceuticals has several drugs in clinical trials, but it only takes one to make this stock a hit.
The Motley Fool
This Pharmaceutical Stock Could Bank Billions Soon
Friday Apr 08 2022 at 06:15
Pieris Pharmaceuticals has several collaborations in place with big pharma.
Pieris Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Pieris Pharmaceuticals’s Altman Z-score is -4.56 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Pieris Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $8.50K of common stock in Pieris Pharmaceuticals on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Pieris Pharmaceuticals’s Income Quality of 1.31 is greater than its Industry Group of 0.69 (89.9% greater)
Pieris Pharmaceuticals’s Income Quality of 1.31 is greater than its Major Industry Group of 0.71 (84.5% greater)
Pieris Pharmaceuticals’s Income Quality of 1.31 is greater than its Sector of 0.75 (74.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Pieris Pharmaceuticals’s Current Ratio of 1.93 is lower than its Industry Group of 4.76 (-59.5% lower)
Pieris Pharmaceuticals’s Current Ratio of 1.93 is lower than its Major Industry Group of 4.32 (-55.3% lower)
Pieris Pharmaceuticals’s Current Ratio of 1.93 is lower than its Sector of 2.6 (-25.8% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.74 & -1.27)
Cannot compare a negative PE Ratio (-1.74 & -1.1)
Cannot compare a negative PE Ratio (-1.74 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Pieris Pharmaceuticals’s PB Ratio of 1.07 is lower than its Industry Group of 1.34 (-20.1% lower)
Pieris Pharmaceuticals’s PB Ratio of 1.07 is lower than its Major Industry Group of 1.4 (-23.6% lower)
Pieris Pharmaceuticals’s PB Ratio of 1.07 is lower than its Sector of 1.62 (-34.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Pieris Pharmaceuticals’s ROE of -0.62 is lower than its Industry Group of -0.44 (-40.9% lower)
Pieris Pharmaceuticals’s ROE of -0.62 is lower than its Major Industry Group of -0.38 (-63.2% lower)
Pieris Pharmaceuticals’s ROE of -0.62 is lower than its Sector of -0.03 (-1966.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Pieris Pharmaceuticals’s ROCE of -0.7 is lower than its Industry Group of -0.42 (-66.7% lower)
Pieris Pharmaceuticals’s ROCE of -0.7 is lower than its Major Industry Group of -0.37 (-89.2% lower)
Pieris Pharmaceuticals’s ROCE of -0.7 is lower than its Sector of -0.04 (-1650.0% lower)
Derived from SEC.GOV filing dataopen_in_new